Re-evaluation of cefepime or piperacillin-tazobactam to decrease use of carbapenems in extended-spectrum beta-lactamase-producing Enterobacterales bloodstream infections (REDUCE-BSI).
Catherine H VuVeena VenugopalanBarbara A SantevecchiStacy A VoilsReuben RamphalKartikeya CherabuddiKathryn DeSearPublished in: Antimicrobial stewardship & healthcare epidemiology : ASHE (2022)
Compared to CBPs, FEP and PTZ did not result in greater mortality or decreased clinical efficacy for the treatment of ESBL-E BSI caused by susceptible organisms.